← Back

Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Price · split & dividend adjusted
News & notes moving BIO
BIO▼

Danaher Bioprocessing Miss Weighs on Bio-Rad Shares

Danaher Corporation's second-quarter bioprocessing unit miss sent ripples across the life sciences sector, pressuring Bio-Rad Laboratories shares in early New York trading. Danaher reported Q2 2026 revenue of $6.3 billion, up 5.5% year-over-year, with adjusted diluted EPS rising 8% to $1.94 and free cash flow of $1.3 billion, and raised its full-year adjusted EPS guidance to $8.45–$8.60. Bio-Rad posted Q2 net sales of $651 million, essentially flat, with its Life Science segment down 4.1% to $252 million, and announced a restructuring plan on July 31, 2026 involving global headcount reductions and facility closures expected to generate $80 million to $90 million in pre-tax charges. RBC Capital subsequently raised its price target on Bio-Rad to $370 from $320, maintaining an Outperform rating, while Danaher named Julie Sawyer Montgomery as CEO. Hedge fund data showed institutional investors trimmed positions in both stocks during Q1 2026, with Bio-Rad held by 35 hedge funds and Danaher by 110.
DHR ▲BIO ▼
Insider Monkey·13dRead more ▾
BIO3

Bio-Rad Q2 2026 earnings show Clinical Diagnostics growth offset by Life Science softness

Bio-Rad Laboratories reported second-quarter 2026 total net sales of approximately $651 million, essentially flat on a reported basis and down 1.9 percent on a currency-neutral basis. Clinical Diagnostics sales were approximately $399 million, an increase of 2.6 percent on a reported basis and 8.3 percent on a currency-neutral basis, led by quality systems, diabetes, and blood typing products. Life Science segment revenue was $252 million, a 5.1 percent currency-neutral decrease driven by academic research challenges and a difficult comparison in process chromatography. Digital PCR instrument revenue increased more than 20 percent, reflecting competitive wins and conversions from traditional qPCR platforms. Non-GAAP operating margin was 12.5 percent, a sequential improvement from 6.6 percent in the first quarter, and non-GAAP net income was $70.2 million, or $2.62 per diluted share. The company reaffirmed its full-year 2026 guidance for currency-neutral revenue growth between minus 3 percent and plus 0.5 percent and non-GAAP operating margin of 10 to 12 percent, while announcing a restructuring expected to yield $30 million to $35 million in annualized net savings by the end of 2027.
BIO
The Motley Fool·15dRead more ▾
BIO

Biocon Fair Value Estimate Raised to ₹429.67 on Margin Focus and Peer Valuation Cues

Simply Wall St has raised its fair value estimate for Biocon to ₹429.67 from ₹416.53, reflecting a shift in peer valuation cues and a greater emphasis on margin improvement plans. The updated model incorporates a lower revenue growth assumption of 14.01% and a reduced net profit margin of 10.73%, while the forward P/E multiple applied to projected earnings increased to 45.01 times from 35.56 times and the discount rate edged down to 13.21% from 13.45%. The revision follows recent analyst actions on peer Bio Rad, where RBC Capital, Citi, and Wells Fargo raised price targets, highlighting that the market is willing to assign higher multiples when there is visibility on execution, even in a tough macro environment. However, Wells Fargo's Equal Weight stance on Bio Rad underscores that execution risk and external headwinds may limit further valuation expansion for companies like Biocon.
BIO
Simply Wall St·17dRead more ▾
Energy Transition & Power Demand▲

Seven-Buyer Aggregation Brings 180 MW Millers Branch Solar Phase II Online in Texas

The 180 MW Phase II portion of the Millers Branch Solar Facility in Haskell County, Texas has achieved commercial operation. The capacity was contracted through Sustainability Roundtable, Inc's Net Zero Consortium for Buyers by Cisco, Juniper Networks (now part of Hewlett Packard Enterprise), Bio-Rad Laboratories, Cadence Design Systems, IDEXX Laboratories, Inc., PTC, and a large healthcare company, which signed an aggregated virtual power purchase agreement with Southern Power Company for the renewable energy credits the project generates. Cisco serves as the anchor buyer for a 50 MW portion, Juniper Networks for 40 MW, Bio-Rad, Cadence, IDEXX, and the healthcare company each for 20 MW, and PTC for 10 MW. This Phase II follows the 200 MW Phase I that reached operation in December 2025 with Thermo Fisher Scientific as sole offtaker, and together with later phases the consortium has surpassed a gigawatt of new renewable energy development. The NZCB is now working toward its Next Gigawatt of Advanced Market Commitments, aiming to bring more than 2 GW of new clean energy online through over $1.5 billion in long-term procurements across North America, Europe, and India.
CSCO ▲PTC ▲BIO ▲CDNS ▲IDXX ▲SO ▲+1
Energy Transition & Power Demand ▲
PR Newswire·22dRead more ▾
Biotech & Genomic Medicine▲

Dye-Free and Label-Free PCR Packaging Market to Reach $1.74 Billion by 2030

The global market for dye-free and label-free packaging for polymerase chain reaction optimization is projected to grow from $0.94 billion in 2025 to $1.06 billion in 2026, and further to $1.74 billion by 2030, at a compound annual growth rate of 13.2%. Growth is driven by rising demand for precision genomic testing, sustainable PCR packaging materials, and automated workflow systems, alongside expansion in personalized medicine and molecular diagnostics. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region. Major companies include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., and Bio-Rad Laboratories Inc.
BIO ▲ROP.SW ▲TMO ▲
Biotech & Genomic Medicine ▲
GlobeNewswire·43dRead more ▾
BIO▼

Charles River Labs Is the Better Medical Research Stock Buy in 2026 Over Bio-Rad

Charles River Laboratories International is the better buy in 2026 compared to Bio-Rad Laboratories, according to a Motley Fool analysis. Charles River is further along in refocusing its business, with fiscal 2026 revenue projected at $3.9 billion and net income swinging back to profitability at $285 million, while Bio-Rad faces headwinds with expected sales of $2.57 billion and net income dropping to $225 million. Charles River also trades at a cheaper forward P/E of 16.6x versus Bio-Rad's 31.95x, despite Bio-Rad's higher current profitability and stronger balance sheet. Both companies are retooling for growth, but Charles River's progress and valuation give it the edge.
CRL ▲BIO ▼
Motley Fool·65dRead more ▾
© 2026 MarketDXAsset